YOLFTbeta
Advagene Biopharma Co. Ltd.

Advagene Biopharma Co. Ltd.

6709 · TWO · Healthcare / Biotechnology

22.15TWD+0.60 (+2.78%)

Price History

Full chart

Market Stats

Previous Close21.55
Open21.60
Day Range21.15 – 22.15
52-Week Range22.50 – 37.35
Volume14.79K
Market Cap1.67B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.39
Dividend Yield0.00%
Beta0.67
50-Day Avg24.81
200-Day Avg26.91

About

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Yu-Shen Hsu
  • Employees16
  • HeadquartersNo.308, Neihu Road, Taipei, Taiwan, 114, Taiwan
  • Websitehttps://www.advagene.com.tw

Leadership

  • Mr. Yu-Shen HsuActing President, GM & Director
  • Mr. Chen BryonFounder & Director

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Income-149.49M-125.66M-98.84M-70.06M-92.56M-118.30M-92.07M-70.82M-70.92M
EBITDA-145.66M-120.57M-94.29M-62.17M-84.83M-106.69M-80.07M-67.09M-65.92M
Net Income-138.13M-111.32M-91.61M-70.16M-92.69M-118.38M-92.11M-69.42M-68.29M
R&D130.94M105.39M70.73M55.33M72.68M100.04M73.22M50.27M50.33M
Interest Expense0032.00K107.00K127.00K81.00K36.00K151.00K175.00K

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets226.23M358.77M279.22M316.26M260.41M140.84M147.93M232.21M166.51M
Total Liabilities12.51M11.88M7.85M16.93M10.84M9.08M7.97M11.67M14.26M
Total Equity213.72M346.89M271.37M299.32M249.57M131.76M139.96M220.54M152.25M
Cash18.64M13.49M12.30M121.89M14.33M18.01M65.19M52.82M55.33M
Total Debt---6.19M4.40M2.57M870.00K--
Net Debt---12.30M-115.70M-9.93M-15.44M-64.32M--

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-177.05M-39.46M-35.69K-30.89M-67.18M-109.35M-77.70M-70.64M-63.33M
Investing Cash Flow-8.65M-203.28M32.75M44.14M-81.52M----
Financing Cash Flow200.00M237.59M1.75K96.34M41.14M-1.26M98.38M--
Capital Expenditure544.00K342.00K6.04M627.00K521.00K10.21M0476.00K2.31M
Free Cash Flow-185.66M-39.80M-6.07M-31.51M-67.70M-119.56M-77.70M-71.12M-65.64M
FCF to OCF104.86%100.87%17011.83%102.03%100.78%109.34%100.00%100.67%103.64%

Key Statistics & Ratios

Market Cap1.67B
Enterprise Value1.41B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book4.87
EPS-1.39
Book Value6.00
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-90.29M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-33.48%
Return on Assets-20.63%
Shares Outstanding69.38M
Shares Float25.28M
Beta0.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 2, 20233457:3426
  • Sep 2, 2020122:121